Field AI tool triages victims of gun violence

Emergency surgery specialists have developed a deep neural network for triaging patients presenting with gunshot wounds.

In a tryout trial, the technique quickly and accurately predicted shock as well as the need for early massive transfusion and major surgery.

The research was conducted at Massachusetts General Hospital and is running in the June edition of the Journal of Trauma and Acute Care Surgery.

Senior author Noelle Saillant, MD, and colleagues trained their field-capable AI tool on data from close to 30,000 patients with gunshot wounds to the trunk or appendage junctions thereof.

Along with wound locations and apparent extents, the training data included vital signs and other basic information that’s usually readily available in the field.

In testing, the tool had a high degree of accuracy predicting shock, transfusion need and surgery urgency, Saillant and co-authors report.

“The presented model is an important proof-of-concept,” they write. “Future iterations will employ an expansion of databases to refine and validate the model, further adding to its potential to improve triage in the field, both in civilian and military settings.”

Study posted here (behind paywall).

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.